- EVX-01 achieved an 80% tumor-specific immune response, surpassing previous rates of 71% and 79%.
- Ongoing Phase 2 trial with KEYTRUDA® for advanced melanoma shows promising potential.
- Trial extended for a third year as data continues to demonstrate robust and durable immune responses.
Evaxion Biotech A/S (EVAX, Financial), a clinical-stage biotech firm, has announced remarkable findings from its personalized cancer vaccine, EVX-01, at the American Association for Cancer Research (AACR) Annual Meeting. The vaccine demonstrated an 80% tumor-specific immune response rate among trial participants, a notable improvement over the previously reported rates of 71% and 79% at ASCO and ESMO 2024 meetings.
EVX-01, developed using Evaxion’s proprietary AI-Immunology™ platform, is being evaluated in a Phase 2 trial in combination with MSD's KEYTRUDA® (pembrolizumab) for the treatment of advanced melanoma. The trial's immune response data reveal strong and persistent effects, which are further enhanced by booster immunizations, suggesting the potential for long-term therapeutic benefits.
In light of these encouraging interim results, Evaxion has extended the trial for a third year to allow for a comprehensive assessment and is on track for a two-year clinical data readout in H2 2025. The ongoing study continues to reaffirm EVX-01's potential as a novel and effective treatment for a broad range of solid tumors.
Birgitte Rønø, Chief Scientific Officer of Evaxion, noted, "We are thrilled by the positive data EVX-01 is generating. The robust and durable immune responses observed are unprecedented and bode well for its future as a cancer treatment."
EVX-01 utilizes a personalized approach, tailoring the vaccine to the unique tumor profile and immune characteristics of each patient. This may not only enhance treatment efficacy but also validate the underlying AI-Immunology™ platform's capability to accurately select therapeutic targets.
